PhageNova Bio (formerly AAVP Biosystems) is a company specializing in cancer treatment. It develops AAVP (adeno-associated virus phage), a hybrid vector platform that infects tumor-associated blood vessels and expresses a variety of gene products, both for therapy and for imaging.